Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort

By sjmartinez • January 8, 2024

Rader F, Oręziak A, Choudhury L, Saberi S, Fermin D, Wheeler MT, Abraham TP, Garcia-Pavia P, Zwas DR, Masri A, Owens A, Hegde SM, Seidler T, Fox S, Balaratnam G, Sehnert AJ, Olivotto I. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort. JACC Heart Fail. 2024 Jan;12(1):164-177. doi: 10.1016/j.jchf.2023.09.028. PMID: 38176782.

Tags: Cardiology/Epi, Cedars Sinai DoM, efficacy, Long-term outcomes, LVOT gradient, NT-proBNP, NYHA functional class, Publications, safety

Parasympathetic response in women with coronary vascular dysfunction during mental stress compared to those with non-cardiac chest pain and reference controls

Mehta PK, Sheikh SA, Dave EK, Shakoor RK, Torbati T, Shah A, Thames MD, Qiang L, Ko YA, Wei J, Shufelt C, Nelson MD, Samuels[...]

Relative Hyperglycemia and In-Hospital Bleeding Across Glycemic Status in Patients on High-Intensity Antithrombotic Therapy

Zhang C, Liu J, Liu W, Liu H, Sun P, Fang Y, Yang J, Sun H, Li Y, Foo RS, Sia CH, Fonarow GC, Yang[...]

Prediction of Cardiovascular Risk Among People with HIV Using the PREVENT Equations Compared to the Pooled Cohort Equations

Durstenfeld MS, McLaughlin MM, Gandhi M, Kornak J, Beatty AL, Hsue PY. Prediction of Cardiovascular Risk Among People with HIV Using the PREVENT Equations Compared[...]